Programme

Ireland Programme – Thursday 11th October 2018


17:00 – 18:00 Arrivals, badge collection & buffet dinner (from 17:30)
18:00 – 18:10 Welcome, Introduction and Overview of Agenda
Professor Elisabeth Vandenberghe
Consultant Haematologist, St. James’ Hospital, Dublin, Ireland
18:10 – 18:35 Targeting DNA damage response defects in haematological malignancies
Professor Tatjana Stankovic
Professor in Cancer Genetics, Institute of Cancer and Genomic Sciences, University of Birmingham, UK
18:35 – 19:00 The many facets of PI3K-delta in immune signalling and cancer
Professor Bart Vanhaesebroeck
Professor of Cell Signalling, UCL Cancer Institute, London
19:00 – 19:25 Advancing strategies to treat patients with relapse/refractory FL
Dr Derville O’Shea
Consultant Haematologist, Cork University Hospital, Ireland
19:25 – 19:30 Chair’s summary & close
Professor Elisabeth Vandenberghe
Consultant Haematologist, St. James’ Hospital, Dublin, Ireland

 

ONC/UK/19-03/PMAR/1117f(1)
Date of preparation: June 2019

This activity is intended for medical Haematology/Oncology healthcare professionals, scientists and academics involved in the management of, and research into CAR T-cell therapy in patients with high-grade lymphoid malignancies, specifically relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), as well as those with interest in the wider treatment landscape of haematological malignancies. Data on licensed CAR-T products will be presented.